Lorenz Hirt
Has grant
Professeur associé médecin adjoint
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Professor Lorenz Hirt is an Associate Professor and Assistant Physician at the Centre Hospitalier Universitaire Vaudois in Switzerland. His research primarily focuses on cerebral metabolism, neuroprotection, and the roles of various biochemical processes in neurological conditions. Recent publications include studies on lactate metabolism, caveolins in the central nervous system, and the impact of DNP polarizing agents in ischemic stroke. He is recognized for his contributions to understanding acute brain injury and cerebrovascular health.
Recent Grants
Grant: Close
Modulation of brain barrier function by microbiota-derived factors in cerebral ischemia
Open Date: 2023-04-01
Close Date: 2026-03-01
Grant: Close
Tracking exogenous lactate at the ultrastructural level in the ischemic mouse brain
Open Date: 2022-12-01
Close Date: 2026-11-01
Grant: Close
Novel theranostic approaches for stroke based on hyperpolarized Magnetic Resonance Imaging
Open Date: 2017-09-01
Close Date: 2020-09-01
Grant: Close
The role of caveolin-1 in blood-brain barrier repair in stroke and traumatic brain injury: towards a general protective strategy for the neurovascular unit
Open Date: 2016-05-01
Close Date: 2019-04-30
Grant: Close
Imaging neuroinflammatory reactions in cerebral ischemia: role of thrombin
Open Date: 2012-03-01
Close Date: 2015-08-31
Articles (23)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Background Pulsed field ablation (PFA) is a largely nonthermal modality with myocardial selectivity and collateral damage sparing. Cerebrovascular safety remains an important consideration as catheter design and pulse parameters may influence embolic risk. Microembolic signals (MES), detected by transcranial Doppler (TCD) ultrasonography, may offer a sensitive real‐time surrogate for procedural‐related embolic activity. Methods We prospectively compared MES burden between two PFA systems: a multielectrode Pentaspline catheter (Farawave, Boston Scientific) and a more recently introduced variable‐loop circular catheter (VLCC) (Varipulse, Biosense Webster). Consecutive patients undergoing first‐time pulmonary vein isolation for AF were included. ACT targets were > 300 s (Pentaspline) and > 350 s (VLCC), and ablation was delivered according to manufacturer‐recommended workflows. Results Among 23 patients (16 Pentaspline, 7 VLCC), ACT was maintained above respective targets in all, and left atrial dwell time was comparable. The total number of PFA deliveries was significantly higher in the Pentaspline group compared to the VLCC group (51 [46–66] vs. 22 [22–25], p < 0.001). The MES burden was significantly higher with VLCC during ablation time (919 [154–2302] vs. 102 [52–248], p = 0.005). This difference was even higher when normalized by the delivered‐to‐recommended PFA deliveries ratio ( p = 0.005). In addition, MES burden with VLCC displayed markedly greater inter‐patient variability, whereas Pentaspline results were more reproducible (IQR 2148 vs. 196, p < 0.001). Conclusions VLCC PFA was associated with higher and more variable cerebral microembolization compared with the Pentaspline system. These findings underscore the impact of catheter design and energy delivery on embolic load and highlight the need for dedicated cerebrovascular safety evaluation.
Year:
2026
A spinal cord injury (SCI) causes immediate and sustained hemodynamic instability that threatens neurological recovery and impacts quality of life. Here we establish the clinical burden of chronic hypotensive complications due to SCI in 1,479 participants and expose the ineffective treatment of these complications with conservative measures. To address this clinical burden, we developed a purpose-built implantable system based on biomimetic epidural electrical stimulation (EES) of the spinal cord that immediately triggered robust pressor responses. The system durably reduced the severity of hypotensive complications in people with SCI, removed the necessity for conservative treatments, improved quality of life and enabled superior engagement in activities of daily living. Central to the development of this therapy was the head-to-head demonstration in the same participants that EES must target the last three thoracic segments, and not the lumbosacral segments, to achieve the safe and effective regulation of blood pressure in people with SCI. These findings in 14 participants establish the path to designing a pivotal device trial that will evaluate the safety and efficacy of EES to treat the underappreciated, treatment-resistant hypotensive complications due to SCI.
Year:
2025
Tracking hyperpolarized (HP) 13 C labeling from either [1‐ 13 C] pyruvate or [1‐ 13 C] lactate is a useful tool to assess intermediary metabolism in vivo, which has already been translated from preclinical to clinical research. HP [1‐ 13 C] pyruvate and [1‐ 13 C] lactate provide complementary views on the same metabolic pathway, and both have been tested as potential neuroprotective agents in the context of acute brain injuries, with more convincing evidence for a beneficial effect of lactate. Our aim here was to investigate and compare HP [1‐ 13 C] pyruvate and [1‐ 13 C] lactate performance as metabolic contrast agents in the brains of healthy mice and mice subjected to middle cerebral artery occlusion, a model of ischemic stroke. We analyzed the metabolite ratios and quantified the real‐time apparent kinetic rates of their cerebral metabolism. We found that the cerebral metabolism of both HP [1‐ 13 C] pyruvate and HP [1‐ 13 C] lactate showed significant alterations after transient cerebral ischemia in mice, reflecting the damage as well as the metabolic reprogramming set in motion to meet the energetic demands in the acute phase of stroke. There was a significant decrease in metabolite ratios (cLPR, cAPR for pyruvate bolus and cPLR, cALR for lactate bolus) and kinetic rates (c k PL for pyruvate bolus and c k LP for lactate bolus). These values progressively decreased from sham to 1 h and 2 h after reperfusion measurements. Overall, while pyruvate is better established as an imaging probe, and lactate appears advantageous on the therapeutic side, both bring information to interrogate brain metabolism in physiological and pathophysiological conditions in real time. This study prepares the ground for further investigation to fully exploit the potential of HP metabolic contrasts for stroke theranostics.
Year:
2025
Ischemic stroke leads to neuronal death, neuroinflammation, blood-brain barrier breakdown, and disruption of the brain–immune–gut (BIG) axis. Despite improvements in recanalization treatments, stroke remains the second leading cause of death globally. Post-stroke infections (PSIs) are the main life-threatening complication (30–45% of all patients and 20% of mortality) after stroke. Traditionally attributed to nosocomial infections /associated medical procedures, ground-breaking research has revealed that PSIs primarily originate from bacterial translocation (BT) following gut barrier disruption after stroke. Despite the high mortality associated with PSIs, current treatments, including antibiotic prophylaxis, are largely ineffective, underscoring the urgent need for a better understanding of their aetiology. Short-chain fatty acids (SCFAs), microbiota-derived metabolites produced by bacterial fermentation of fibres, are key regulators of the BIG axis. SCFAs exert neuroprotective, anti-inflammatory, and antimicrobial effects across models of neurodegenerative and infectious diseases. Using a preclinical stroke model (transient middle cerebral artery occlusion, MCAO) in 12-week-old male mice, we evaluated the effects of SCFA administration starting 24 h after stroke until sacrifice at day 4 on BT, gut integrity, and brain injury. Our findings confirmed that stroke induces BT to several organs ( e . g ., liver, heart, spleen) and, for the first time, demonstrated bacterial presence in the brainstem and the ischemic core of the injured brain. Importantly, we also showed that SCFA treatment significantly reduced BT to several organs. In addition, SCFAs modulated gut barrier integrity, reduced brain lesion size, and improved functional recovery. These findings highlight the crucial role of SCFAs in the BIG axis following stroke and their potential to mitigate not only gut barrier disruption and brain injury, but also infection-related complications, offering a promising therapeutic strategy for one of the least understood yet most lethal complications of stroke.
Year:
2025
The goal of neurocritical care is to prevent and reverse the pathologic cascades of secondary brain injury by optimizing cerebral blood flow, oxygen supply and substrate delivery. While glucose is an essential energetic substrate for the brain, we frequently observe a strong decrease in glucose delivery and/or a glucose metabolic dysregulation following acute brain injury. In parallel, during the last decades, lactate and ketone bodies have been identified as potential alternative fuels to provide energy to the brain, both under physiological conditions and in case of glucose shortage. They are now viewed as integral parts of brain metabolism. In addition to their energetic role, experimental evidence also supports their neuroprotective properties after acute brain injury, regulating in particular intracranial pressure control, decreasing ischemic volume, and leading to an improvement in cognitive functions as well as survival. In this review, we present preclinical and clinical evidence exploring the mechanisms underlying their neuroprotective effects and identify research priorities for promoting lactate and ketone bodies use in brain injury.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Collaborators (13)
ELENA GONZALEZ-REY
Principal Research Scientist
Instituto de Parasitología y Biomedicina López-Neyra
Luc Pellerin
Professeur des Universités et Praticien Hospitalier
University of Poitiers
Jean‐Yves Chatton
Director
University of Lausanne
Bernard Lanz
Researcher / Lecturer
École Polytechnique Fédérale de Lausanne
Hélène Roumes
Centre de Résonance Magnétique des Systèmes Biologiques
Nelleke Langerak
Senior researcher / lecturer
HU University of Applied Sciences
Gregoire Wuerzner
Medical director
Lausanne University Hospital
Andreas Rowald
Associate Professor
Friedrich-Alexander Universität Erlangen-Nürnberg
Thanh Phong Lê
EPFL (École Polytechnique Fédérale de Lausanne)
Laura Moniek Ronda De Herde
Aalborg University
José Luis Ruiz Rodríguez
University of Zurich
Julia Castillo-González
Post-doctoral researcher
Instituto de Parasitología y Biomedicina López-Neyra
Jean-Noel Hyacinthe
Associate Professor
EPFL (École Polytechnique Fédérale de Lausanne)
Make your next move.
Prepare your application
Review drafts before you send them.